Seeking Alpha

Threshold Pharmaceuticals (THLD) +6.3% premarket after earning a $30M milestone payment from...

Threshold Pharmaceuticals (THLD) +6.3% premarket after earning a $30M milestone payment from drug partner Merck (MRK), which started a late-stage study of THLD's pancreatic cancer drug. TH-302 is an investigational hypoxia-targeted drug designed to be activated under severe tumor hypoxic conditions, a hallmark of many cancers.
Comments (1)
  • biochemist
    , contributor
    Comments (418) | Send Message
     
    SA Editors - Merck KgA (MRK.DE), the German company, is partnered with THLD on TH-302, not MRK the US pharma.
    25 Jan 2013, 10:52 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs